Examination of HER3 targeting in cancer using monoclonal antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 3, 2015, Pages 839-844

  Gaborit, Nadège ^a   Abdul Haia, Ali ^a   Mancini, Maicol ^a   Lindzen, Moshit ^a   Lavi, Sara ^a   Leitner, Orith ^a   Mounier, Lucile ^b   Chentouf, Myriam ^c   Dunoyer, Sai ^a   Ghosh, Manjusha ^a   Larbouret, Christel ^c   Chardès, Thierry ^c   Bazin, Hervé ^b   Pèlegrin, André ^c   Selaf, Michael ^d   Yardena, Yosef ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

^c Biological Services Weizmann Institute of Science ^*  (France)

^d KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Antibody combination; Cancer therapy; HER3; Signal transduction; Tyrosine kinase

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NG140; MONOCLONAL ANTIBODY NG33; MONOCLONAL ANTIBODY NG533; MONOCLONAL ANTIBODY NG83; MONOCLONAL ANTIBODY XC252; MONOCLONAL ANTIBODY XC90; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; TRASTUZUMAB; UNCLASSIFIED DRUG; ERBB3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOCRINE EFFECT; BINDING AFFINITY; CANCER INHIBITION; CANCER RESISTANCE; CANCER THERAPY; CELL CULTURE; CELL GROWTH; CELL INTERACTION; CELL MEDIATED CYTOTOXICITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; EFFECTOR CELL; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STROMA CELL; THERAPY EFFECT; DRUG DELIVERY SYSTEM; IMMUNOLOGY; TUMOR CELL LINE;

ANIMALIA;

ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; HUMANS; RECEPTOR, ERBB-3;

EID: 84921417367     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1423645112     Document Type: Article

References (47)

1. Witsch E, Sela M, Yarden Y (2010) Roles for growth factors in cancer progression. Physiology (Bethesda) 25(2):85-101.
2. Barros FF, Powe DG, Ellis IO, Green AR (2010) Understanding the HER family in breast cancer: Interaction with ligands, dimerization and treatments. Histopathology 56(5): 560-572.
3. Lax I, et al. (1988) Localization of a major receptor-binding domain for epidermal growth factor by affinity labeling. Mol Cell Biol 8(4):1831-1834.
4. Burgess AW (2008) EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors 26(5):263-274.
5. Clayton AH, et al. (2005) Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem 280(34):30392-30399.
6. Garrett TP, et al. (2002) Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 110(6): 763-773.
7. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137.
8. Shi F, Telesco SE, Liu Y, Radhakrishnan R, Lemmon MA (2010) ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation. Proc Natl Acad Sci USA 107(17):7692-7697.
9. Jaiswal BS, et al. (2013) Oncogenic ERBB3 mutations in human cancers. Cancer Cell 23(5):603-617.
10. Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77(6):400-410.
11. Schmitz KR, Ferguson KM (2009) Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 315(4):659-670.
12. Narayan M, et al. (2009) Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res 69(6):2191-2194.
13. Garrett JT, et al. (2011) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 108(12):5021-5026.
14. Lu Y, et al. (2007) Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 67(17):8240-8247.
15. Wheeler DL, et al. (2008) Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene 27(28):3944-3956.
16. Desbois-Mouthon C, et al. (2009) Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: Rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor in hepatocellular carcinoma. Clin Cancer Res 15(17):5445-5456.
17. Kruser TJ, Wheeler DL (2010) Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res 316(7):1083-1100.
18. Ben-Kasus T, Schechter B, Sela M, Yarden Y (2007) Cancer therapeutic antibodies come of age: Targeting minimal residual disease. Mol Oncol 1(1):42-54.
19. Ferraro DA, et al. (2013) Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci USA 110(5):1815-1820.
20. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci USA 106(9):3294-3299.
21. Friedman LM, et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 102(6):1915-1920.
22. Miles D, et al. (2013) Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: Subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). Breast Cancer Res Treat 142(1):89-99.
23. Gala K, Chandarlapaty S (2014) Molecular pathways: HER3 targeted therapy. Clin Cancer Res 20(6):1410-1416.
24. Chen X, et al. (1996) An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB-3 and ErbB-4. J Biol Chem 271(13): 7620-7629.
25. Lazrek Y, et al. (2013) Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia 15(3):335-347.
26. Thomas G, et al. (2014) HER3 as biomarker and therapeutic target in pancreatic cancer: New insights in pertuzumab therapy in preclinical models. Oncotarget 5(16): 7138-7148.
27. Aurisicchio L, Marra E, Roscilli G, Mancini R, Ciliberto G (2012) The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 3(8):744-758.
28. Baselga J, Swain SM (2009) Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463-475.
29. Jiang N, Saba NF, Chen ZG (2012) Advances in targeting HER3 as an anticancer therapy. Chemother Res Pract 2012:817304.
30. Kol A, et al. (2014) HER3, serious partner in crime: Therapeutic approaches and potential biomarkers for effect of HER3-targeting. Pharmacol Ther 143(1):1-11.
31. Pedersen MW, et al. (2010) Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70(2):588-597.
32. Drebin JA, Link VC, Greene MI (1988) Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2(3):273-277.
33. Kasprzyk PG, Song SU, Di Fiore PP, King CR (1992) Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52(10):2771-2776.
34. Révillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP (2008) ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19(1):73-80.
35. Khambata-Ford S, et al. (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25(22):3230-3237.
36. Sheng Q, et al. (2010) An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell 17(3):298-310.
37. Dienstmann R, et al. (2013) Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC). J Clin Oncol 31(15 Suppl):abstr 3551.
38. Machiels J-PH, et al. (2013) Sym004, a novel strategy to target EGFR with an antibody mixture, in patients with advanced SCCHN progressing after anti-EGFR monoclonal antibody: A proof of concept study. J Clin Oncol 31(15 Suppl):abstr 6002.
39. Spiridon CI, et al. (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8(6):1720-1730.
40. Waterman H, et al. (2002) A mutant EGF-receptor defective in ubiquitylation and endocytosis unveils a role for Grb2 in negative signaling. EMBO J 21(3):303-313.
41. Jiang X, Huang F, Marusyk A, Sorkin A (2003) Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell 14(3):858-870.
42. Levkowitz G, et al. (1999) Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 4(6):1029-1040.
43. Sak MM, et al. (2012) The oncoprotein ErbB3 is endocytosed in the absence of added ligand in a clathrin-dependent manner. Carcinogenesis 33(5):1031-1039.
44. Waterman H, Sabanai I, Geiger B, Yarden Y (1998) Alternative intracellular routing of ErbB receptors may determine signaling potency. J Biol Chem 273(22):13819-13827.
45. rd (2007) Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1. Mol Cell Biol 27(6):2180-2188.
46. Huang Z, et al. (2014) The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling. Oncogene.
47. Jacobs B, et al. (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27(30):5068-5074.